| First Author | Shi C | Year | 2014 |
| Journal | J Steroid Biochem Mol Biol | Volume | 144 Pt B |
| Pages | 280-5 | PubMed ID | 25017047 |
| Mgi Jnum | J:311709 | Mgi Id | MGI:6760184 |
| Doi | 10.1016/j.jsbmb.2014.06.010 | Citation | Shi C, et al. (2014) Estrogen receptor alpha promotes non-amyloidogenic processing of platelet amyloid precursor protein via the MAPK/ERK pathway. J Steroid Biochem Mol Biol 144 Pt B:280-5 |
| abstractText | Deposition of amyloid beta peptide (Abeta), a proteolytic product of amyloid precursor protein (APP), in senile plaques and in the walls of cerebral blood vessels is a hallmark of Alzheimer's disease (AD). Platelets contain high levels of APP and Abeta and may contribute to amyloid deposits seen in AD. However, the biochemical mechanism(s) involved in the regulation of platelet APP metabolism are largely unknown. The estrogen receptor alpha (ERalpha) is found to be expressed in platelets. It has not been elucidated whether ERalpha-mediated non-genomic signaling intervenes with platelet APP processing. Using ERalpha knock-out (alpha-ERKO) mice and wild type (WT) littermates, the present study demonstrated that ERalpha-specific agonist propylpyrazole triol (PPT) promoted non-amyloidogenic processing of platelet APP via the mitogen-activated protein kinase (MAPK)/extracellular-signal-regulated kinase (ERK) pathway. The underlying basis involves direct association of activated ERK with a disintegrin and metalloprotease domain 17 (ADAM17, an alpha-secretase candidate) and ERK-dependent threonine phosphorylation of ADAM17. These results suggest that selective modulation of ERalpha in peripheral target tissues may serve as an anti-amyloidogenic strategy for AD and other amyloidogenic diseases. |
